Rubisandin

Rubisandin

epirubicin

Manufacturer:

Sanbe
Concise Prescribing Info
Contents
Epirubicin HCl
Indications/Uses
Monotherapy or combination therapy in breast, gastric, lung, malignant lymphomas & soft tissue sarcoma. Intravesical administration in the treatment of papillary transitional cell carcinoma of the bladder, carcinoma-in situ & in the prophylaxis of recurrences after transurethral resection.
Dosage/Direction for Use
Adult Conventional Dose: 75-90 mg/m2 IV over 3-5 min repeated at 21-day intervals. High dose: Small cell lung cancer (previously untreated) 120 mg/m2 on day 1 every 3 wk. Non-small cell lung cancer (squamous, large cell & adenocarcinoma previously untreated) 135 mg/m2 on day 1 or 45 mg/m2 on days 1, 2 & 3 every 3 wk given as an IV bolus over 3-5 min or as an infusion for up to 30 min. Advanced breast cancer 135 mg/m2 in monotherapy & 120 mg/m2 in combination therapy every 3-4 wk divided over 2-3 successive days. Papillary carcinoma & carcinoma-in situ 50 mg/mL (diluted w/ saline or distilled sterile water) once wkly for 8 wk. For carcinoma-in situ, dose may be increased up to 80 mg/50 mL. Prophylaxis 50 mg/50 mL once wkly for 4 wk, repeated after 11 mth. Retain soln intravesically for 1 hr.
Contraindications
Marked myelosuppression, patients treated w/ max cumulative doses of other anthracyclines eg doxorubicin & daunorubicin, current or previous history of cardiac impairment. Pregnancy & lactation.
Special Precautions
Leucopenia, neutropenia. Monitor RBC, WBC, neutrophils & platelet count, liver function (SGOT, SGPT, alkaline phosphatase, bilirubin) & cardiac function before & during treatment; cardiotoxicity, heart failure, concomitant or prior radiotherapy to the mediastinal-pericardial area; potentially cardiotoxic drugs; cardiomyopathy; monitor ECG, echocardiography & left ventricular ejection fraction before & after treatment cycle. Hyperuricemia; monitor blood uric acid levels. May cause red coloration of urine for 1-2 days after initiation. Intravesical administration: chemical cystitis. May affect ability to drive or operate machinery.
Adverse Reactions
Myelosuppression, cardiotoxicity, alopecia, mucositis, GI disturbances (eg, nausea, vomiting, diarrhoea), hyperpyrexia.
ATC Classification
L01DB03 - epirubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Presentation/Packing
Form
Rubisandin inj 50 mg/25 mL
Packing/Price
1's (Rp1,184,600/boks)
Form
Rubisandin inj 10 mg/5 mL
Packing/Price
1's (Rp274,650/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in